"In vitro" activities of antimycobacterial agents against Mycobacterium avium subsp. paratuberculosis linked to Crohn's Disease and Paratuberculosis

Stefania Zanetti,Sara Cannas,Niyaz Ahmed,Silvia Ortu,Paola Molicotti,Leonardo A Sechi

doi:10.1186/1476-0711-5-27

Abstract

Crohn's disease, a human disease similar to paratuberculosis in animals is the most painful and devastating disease that may involve infection with M. avium subsp. paratuberculosis (MAP), different genetic polymorphisms and an immune dysregulation syndrome. Treatment of Crohn's disease is most commonly based on 5-aminosalicylic acid (5-ASA) compounds, corticosteroids, and immunosuppressive agents. Recently, biological therapies using monoclonal antibodies against inflammatory cytokines have shown some positive results. However, all these therapies treat the symptoms not the cause of the disease.

Highlights

Crohn's disease, a human disease similar to paratuberculosis in animals is the most painful and devastating disease that may involve infection with M. avium subsp. paratuberculosis (MAP), different genetic polymorphisms and an immune dysregulation syndrome [1,2,3,4,5]
Considering the worldwide magnitude and impact of health concerns caused by MAP, we studied antimycobacterial activity of different antituberculosis agents in vitro against MAP bacilli of human and veterinary origins
We were interested to investigate the variability of susceptibility to antimycobacterial compounds of the MAP isolates with respect to growth in agar medium and Congo red staining properties

Summary

Introduction

Crohn's disease, a human disease similar to paratuberculosis in animals is the most painful and devastating disease that may involve infection with M. avium subsp. paratuberculosis (MAP), different genetic polymorphisms and an immune dysregulation syndrome [1,2,3,4,5]. Crohn's disease, a human disease similar to paratuberculosis in animals is the most painful and devastating disease that may involve infection with M. avium subsp. Considering the worldwide magnitude and impact of health concerns caused by MAP, we studied antimycobacterial activity of different antituberculosis agents in vitro against MAP bacilli of human and veterinary origins.

Results

Conclusion